Buddy Lyons
Value, long/short equity, contrarian, growth

Impax Labs: Beyond The Hayward Debacle, High Reward, Manageable Risk

Impax Laboratories Inc. (NASDAQ:IPXL) is engaged in the development, manufacture and marketing of generic (72% of revenue) and branded pharmaceuticals (28%). Impax has 44 ANDAs at the FDA and is developing another 25 generic products. In the branded area, the company had licensed Zomig (migraines) from AstraZeneca (NYSE:AZN) in February 2012. It was a strategic move that brought the company significant revenue and enabled the company to build sales and infrastructure for the marketing of Rytary, a long-acting reformulation of levodopa (a dopamine precursor) for treating Parkinson's Disease, currently awaiting approval. Rytary would be an important incremental advance in the treatment of Parkinson's since it would have reduced the "on-off" periods of regular levodopa. Rytary is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details